Compare PANL & ENGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PANL | ENGN |
|---|---|---|
| Founded | 1996 | 1999 |
| Country | United States | Canada |
| Employees | N/A | N/A |
| Industry | Marine Transportation | |
| Sector | Consumer Discretionary | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 414.5M | 379.3M |
| IPO Year | N/A | N/A |
| Metric | PANL | ENGN |
|---|---|---|
| Price | $7.39 | $8.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 1 | 7 |
| Target Price | $9.00 | ★ $22.71 |
| AVG Volume (30 Days) | 332.5K | ★ 528.5K |
| Earning Date | 11-06-2025 | 12-19-2025 |
| Dividend Yield | ★ 2.80% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $595,335,937.00 | N/A |
| Revenue This Year | $18.51 | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $26.74 | ★ N/A |
| Revenue Growth | ★ 14.22 | N/A |
| 52 Week Low | $3.93 | $2.65 |
| 52 Week High | $7.38 | $11.14 |
| Indicator | PANL | ENGN |
|---|---|---|
| Relative Strength Index (RSI) | 70.88 | 55.41 |
| Support Level | $7.04 | $7.77 |
| Resistance Level | $7.38 | $9.14 |
| Average True Range (ATR) | 0.21 | 0.60 |
| MACD | -0.04 | 0.06 |
| Stochastic Oscillator | 95.00 | 58.43 |
Pangaea Logistics Solutions Ltd and its subsidiaries provide seaborne drybulk logistics and transportation services. It transports various drybulk cargoes including grains, coal, iron, ore, pig, iron, hot briquetted iron, bauxite, alumina, cement clinker, dolomite, and limestone. The company provides ocean transportation services to clients utilizing an ocean-going fleet of motor vessels in the Handymax, Supramax, Ultramax, Panamax, and Post-Panamax segments. Its services include cargo loading, cargo discharge, vessel chartering, voyage planning, and technical vessel management. The company derives all of its revenues from contracts of affreightment, voyage charters and time charters. Geographically, it derives key revenue from the United States, followed by Canada, Germany, and others.
enGene Holdings Inc is a clinical-stage biotechnology company focused on developing gene therapies to improve the lives of patients. The Company is developing non-viral gene therapies based on its novel and proprietary dually derived chitosan, or DDX, gene delivery platform, which allows localized delivery of multiple gene cargos directly to mucosal tissues and other organs.